A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya (COV004)

niversity of Oxford0 个研究点目标入组 400 人开始时间: 2020年4月26日最近更新: 2023年5月29日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: niversity of Oxford
入组人数: 400

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 19 Year(s) 至 44 Year(s)（—）
性别: All

入选标准

•Frontline Staff as defined by the Government of Kenya (including healthcare workers, allied health professionals, truckers, security personnel, banking personnel, supermarket staff, police, security personnel, prison workers, laboratory technicians, scientists, logistics personnel, public transport workers including aviation industry amongst others) and other members of public.
•Healthy adults aged 18-55 years for phase Ib, =18 years for phase II.
•Able and willing (in the Investigators’ opinion) to comply with all study requirements, including making visits to KEMRI CGMRC or other designated study health facility for follow up under conditions with limited transport.
•Agreement to refrain from blood donation during the course of the study
•Use of effective method of contraception for duration of study for female participants. They should use effective contraception for 30 days prior to vaccination. For female participants, we will ask them to attend with their family planning records for verification. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject’s entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
•Provide written informed consent.
•Plan to remain resident in the study area for 1 year following vaccination

排除标准

•Prior receipt of any vaccines (licensed or investigational) =30 days before
•Volunteer who is not literate.
•Planned receipt of any vaccine other than the study intervention within 30 days
•before or after study vaccination.
•Prior receipt of an investigational or licensed vaccine likely to impact on
•interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus
•Planned or ongoing participation in any other interventional studies (of licensed or
•investigational products) =30 days before enrolment and for the duration of the
•Administration of immunoglobulins and/or any blood products within the three
•months preceding the planned administration of the vaccine candidate.
•Any confirmed or suspected immunosuppressive or immunodeficient state,
•including HIV infection; asplenia; recurrent severe infections and chronic use
•(more than 14 days) immunosuppressant medication within the past 6 months
•(inhaled and topical steroids are allowed).
•History of allergic disease or reactions likely to be exacerbated by any component
•of the vaccine.
•Any history of hereditary or idiopathic angioedema.
•Pregnancy, lactation or willingness/intention to become pregnant during the study.
•History of cancer (except basal cell carcinoma of the skin and cervical carcinoma
•History of serious psychiatric condition likely to affect participation in the study.
•Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or
•prior history of significant bleeding or bruising following IM injections or
•venepuncture.
•Any other serious chronic illness requiring hospital specialist supervision.
•Suspected or known current alcohol abuse as defined by an alcohol intake of
•greater than 42 units every week (e.g. more than 2 bottles of 500mls Tusker (beer)
•a day, more than 2 large glasses of 12% wine per day)

研究者

发起方

niversity of Oxford

相似试验

进行中（未招募）

不适用

A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly 60 years and older. - FLU-LD-003Immunization against influenza in male and female subjects aged 60 years and older.

EUCTR2006-002680-18-BEGlaxoSmithKline Biologicals

进行中（未招募）

1 期

A study on the safety, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide against chronic Hepatitis B (CHB) and chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.Hepatitis B virus (HBV) infectionMedDRA version: 20.0Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestations

EUCTR2021-003567-10-FRGlaxoSmithKline Biologicals184

进行中（未招募）

1 期

EUCTR2021-003567-10-BEGlaxoSmithKline Biologicals174

进行中（未招募）

1 期

EUCTR2021-003567-10-ESGlaxoSmithKline SA184

进行中（未招募）

1 期

EUCTR2021-003567-10-ITGLAXOSMITHKLINE BIOLOGICALS245